Send to

Choose Destination
J Hepatol. 2001 Jul;35(1):134-46.

Ursodeoxycholic acid 'mechanisms of action and clinical use in hepatobiliary disorders'.

Author information

Division of Gastroenterology and Hepatology, Mayo Clinic and Foundation, 55905, USA.


UDCA exerts its beneficial effect in liver diseases through a diverse, probably, complementary array of mechanisms. The clinical use and efficacy of UDCA in PBC have been evident. UDCA may also have a place in the management of PSC, ICP, cystic fibrosis, PFIC and GVHD involving the liver, although, more studies are needed to further determine its therapeutic potential in these diseases and in other hepatobiliary disorders such as liver allograft rejection, drug and TPN-induced cholestasis, NASH, and alcoholic liver disease.

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center